Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study

Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study

Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin, including patient-reported outcomes, in routine practice in three European countries: the CMPASS-EU cohort study. Objectives: To identify patient characteristics associated with routine prescription of daclatasvir (DCV) in chronic...

Full description

Bibliographic Details
Main Authors: Stefan Bourgeois, Karel van Erpecum, Jean Delwaide, Uwe Naumann, Stefan Christensen, Christophe Moreno, Anita Pathil, Emile Schippers, Nancy van Emmerik, Benoit Caritey, Conrad Fischer, Florence Mercier, Joerg Petersen
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Cogent Medicine
Subjects:
hepatitis c
daclatasvir
sofosbuvir
ribavirin
real-world
quality-of-life
efficacy
safety
cirrhosis
hiv coinfection
Online Access:http://dx.doi.org/10.1080/2331205X.2020.1727169

Internet

http://dx.doi.org/10.1080/2331205X.2020.1727169

Similar Items